Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
Status:
Terminated
Trial end date:
2020-03-31
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, phase 1 study conducted to test intratumoral injections of
TTI-621 in subjects that have relapsed and refractory percutaneously accessible solid tumors
or mycosis fungoides.
The study will be performed in two different parts. Part 1 is the Dose Escalation phase and
Part 2 is the Dose Expansion phase.
The purpose of this study is to characterize the safety profile of TTI-621 and to determine
the optimal dose and delivery schedule of TTI-621. In addition, the safety and antitumor
activity of TTI-621 will be evaluated in combination with other anti-cancer agents or
radiation.
Phase:
Phase 1
Details
Lead Sponsor:
Trillium Therapeutics Inc.
Treatments:
Immune Checkpoint Inhibitors Immunoglobulin G Interferons Talimogene laherparepvec